🇮🇳India

दवा की समाप्ति से नुकसान (Financial Loss from Medicine Expiry)

2 verified sources

Definition

Overordered inventory sits on shelves beyond expected sale windows. Expiry dates are reached, requiring pharmacies to write off medicines as loss or violate Drugs and Cosmetics Rules by selling expired stock.

Key Findings

  • Financial Impact: 2–5% of inventory value written off annually; typical chain (₹5 crore inventory value): ₹10–25 lakhs annual expiry loss
  • Frequency: Monthly, during physical stock counts and expiry audits
  • Root Cause: Manual expiry monitoring; static ordering without considering batch shelf-life; overstocking in low-turnover locations

Why This Matters

The Pitch: Indian pharmacy retailers waste ₹50–150 lakhs annually on expired medicine write-offs due to poor inventory aging. Automated expiry tracking and demand-driven ordering eliminate this waste.

Affected Stakeholders

Store Manager, Pharmacist, Compliance Officer

Deep Analysis (Premium)

Financial Impact

Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.

Unlock to reveal

Current Workarounds

Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.

Unlock to reveal

Get Solutions for This Problem

Full report with actionable solutions

$99$39
  • Solutions for this specific pain
  • Solutions for all 15 industry pains
  • Where to find first clients
  • Pricing & launch costs
Get Solutions Report

Methodology & Sources

Data collected via OSINT from regulatory filings, industry audits, and verified case studies.

Evidence Sources:

Related Business Risks

अनुपलब्धता पर नियामक जुर्माना (Regulatory Fines for Medicine Unavailability)

Estimated penalty per complaint: ₹5,000–₹50,000 (typical regulatory fine range); cumulative annual fines for major retailers: ₹50 lakhs to ₹5 crores+ depending on complaint frequency

अतिरिक्त स्टॉक से मुनाफा हानि (Profit Loss from Excess Inventory)

17% of net profit (HARD evidence from research); typical annual profit loss: ₹2–5 crores for mid-sized retail pharmacy chains (100+ locations)

स्टॉकआउट से बिक्री हानि (Lost Sales from Stockouts)

5–12% of annual revenue; typical pharmacy chain (₹50 crore annual turnover): ₹2.5–6 crores annual lost sales

स्थान-अलग इन्वेंटरी निर्णयों से अनावश्यक ओवरस्टॉकिंग (Overstocking from Location-Siloed Decisions)

₹1–3 crores annually for mid-sized pharmacy chains; represents 10–15% excess inventory across multi-location networks

ड्रग्स एंड कॉस्मेटिक्स अनुपालन दंड और लाइसेंस निलंबन

₹2,00,000 - ₹50,00,000 per license suspension (industry-estimated operational loss during closure); Permanent license revocation = total business loss; Typical pharmacy revenue per month: ₹20,00,000 - ₹1,00,00,000 (estimated 10-50 day closure risk per audit cycle)

तीसरे पक्ष के ऑडिट दस्तावेज़ प्रतिक्रिया में क्षमता हानि

30 hours/audit cycle × ₹200-₹400/hour (pharmacist time) = ₹6,000 - ₹12,000 per audit; Plus estimated lost pharmacy revenue during reduced dispensing capacity: ₹15,000 - ₹30,000 per audit cycle (2-3 audits/year = ₹45,000 - ₹90,000/year per pharmacy)

Request Deep Analysis

🇮🇳 Be first to access this market's intelligence